Search
Research
CFC ReportThe Tasmanian Government has made a significant commitment in recent years to ensure children have the best possible start in life.
Research
Children’s regenerative and genetic medicine programThe project aims to build capacity in regenerative medicine for children with respiratory diseases.

The CIRCA DIEM Study is a multicentre study, involving several different hospital sites across Australia. Here, you can find out more about which hospitals recruit babies into the CIRCA DIEM Study.
Research
Coalition to Advance Vaccines Against Group A Streptococcus (CANVAS): A Trans-Tasman Initiative Against Rheumatic FeverCANVAS is a commitment by the Governments of Australia and New Zealand to advance the development of a vaccine against GAS infection, which can cause rheumatic fever.
Research
Colostrum, the missing link for healthy growthValerie Verhasselt MD, PhD Head, Immunology and Breastfeeding 0402997617 Valerie.verhasselt@thekids.org.au Head, Immunology and Breastfeeding @
Research
Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody testPeter Richmond MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials Group
Research
Complex Experiences of Gender AffirmationThis project explores the mental health and support needs of Australians with complex experiences of gender-affirmation.

Explore some of the frequently asked questions that The C3 Study receives.
Research
Developing a human challenge model of GAS infectionNHMRC funding has been awarded for 4 years to Murdoch Childrens Research Institute for this project, with collaboration from Professor Jonathan Carapetis at The Kids.
Research
Developing new immune based therapies for neuroblastomaNeuroblastoma is a complex childhood cancer of the nerve cells and the most common solid tumour in children outside of the brain. The average age of diagnosis is 1-2 years and tragically 50% of children with high-risk neuroblastoma lose their battle within five years.